KR102469853B1
(en)
|
2008-04-11 |
2022-11-22 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
JP5766124B2
(en)
|
2009-01-21 |
2015-08-19 |
アムジェン インコーポレイテッド |
Compositions and methods for the treatment of inflammatory and autoimmune diseases
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5953303B2
(en)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
Antibodies with modified isoelectric points
|
MX352889B
(en)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Fcîriib-specific fc antibody.
|
CN103533951B
(en)
|
2011-04-08 |
2017-04-19 |
安姆根有限公司 |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
BR112013032630B1
(en)
|
2011-06-30 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
HETERODIMERIZED POLYPEPTIDE COMPRISING IGG FC REGION
|
UA117901C2
(en)
*
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Antibody variants and uses thereof
|
WO2013047748A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
TW201817745A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013081143A1
(en)
*
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
Drug containing carrier into cell for forming immune complex
|
US9714276B2
(en)
*
|
2012-01-26 |
2017-07-25 |
Amgen Inc. |
Growth differentiation factor 15 (GDF-15) polypeptides
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
SG10201709559PA
(en)
|
2012-08-24 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
JP6273205B2
(en)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
Heterodimeric protein composition
|
DK2940135T5
(en)
|
2012-12-27 |
2021-09-20 |
Chugai Pharmaceutical Co Ltd |
Heterodimerized polypeptide
|
EP2943506B1
(en)
*
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3424952A1
(en)
|
2013-03-15 |
2019-01-09 |
Amgen, Inc |
Heterodimeric bispecific antibodies
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
AP2015008732A0
(en)
|
2013-03-15 |
2015-09-30 |
Amgen Inc |
Human pac1 antibodies
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
RU2687043C2
(en)
*
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE
|
EP2992012B1
(en)
|
2013-04-29 |
2019-07-17 |
F.Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
EP3004174B1
(en)
*
|
2013-05-31 |
2019-04-17 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
EA202092386A1
(en)
|
2013-07-31 |
2021-04-30 |
Эмджен Инк. |
CONSTRUCTIONS BASED ON DIFFERENTIATION AND GROWTH FACTOR 15 (GDF15)
|
EP3733710A1
(en)
|
2013-09-25 |
2020-11-04 |
Amgen, Inc |
Hetrodimeric v-c-fc-v-c antibody
|
TWI652279B
(en)
|
2013-11-11 |
2019-03-01 |
中外製藥股份有限公司 |
Antigen-binding molecules containing altered antibody variable regions
|
EP3842455A1
(en)
|
2014-01-15 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
DK3143138T3
(en)
|
2014-05-13 |
2022-04-25 |
Bioatla Inc |
CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS
|
SG11201609707WA
(en)
|
2014-07-01 |
2017-01-27 |
Pfizer |
Bispecific heterodimeric diabodies and uses thereof
|
WO2016030350A1
(en)
*
|
2014-08-29 |
2016-03-03 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
CA2960756C
(en)
|
2014-09-15 |
2023-08-01 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
US20170247476A1
(en)
|
2014-09-25 |
2017-08-31 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
CA2960797A1
(en)
*
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
BR112017009764A2
(en)
|
2014-11-10 |
2018-02-20 |
Hoffmann La Roche |
bispecific antibodies and methods of use in ophthalmology
|
KR20170082594A
(en)
*
|
2014-11-10 |
2017-07-14 |
에프. 호프만-라 로슈 아게 |
Anti-ang2 antibodies and methods of use
|
TW202313697A
(en)
|
2014-11-11 |
2023-04-01 |
日商中外製藥股份有限公司 |
Library of antigen-binding molecules including modified antibody variable region
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
BR112017011166A2
(en)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
heterodimeric antibodies that bind to cd3 and cd38
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
MX2017012966A
(en)
|
2015-04-10 |
2018-06-06 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells.
|
TW202144411A
(en)
*
|
2015-07-23 |
2021-12-01 |
德商包林格因蓋爾漢國際股份有限公司 |
Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
|
EP3352760A4
(en)
|
2015-09-21 |
2019-03-06 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
MA43567A
(en)
|
2015-12-15 |
2018-11-14 |
Amgen Inc |
PACAP ANTIBODIES AND THEIR USES
|
KR20230051602A
(en)
|
2016-04-15 |
2023-04-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos ligand variant immunomodulatory proteins and uses thereof
|
KR20190006495A
(en)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
CD80 variant immunoregulatory proteins and uses thereof
|
CN109475627B
(en)
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
Antibody mixtures
|
MX2018015592A
(en)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Bispecific checkpoint inhibitor antibodies.
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
FR3053688A1
(en)
*
|
2016-07-06 |
2018-01-12 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
FC MUTANTS WITH IMPROVED FUNCTIONAL ACTIVITY
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
CN110088127A
(en)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
CD155 variant immune modulator and application thereof
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
EP3497120A1
(en)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
EP3579848A4
(en)
|
2017-02-08 |
2021-03-03 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
AU2018221731C1
(en)
|
2017-02-17 |
2021-11-18 |
Denali Therapeutics Inc. |
Engineered transferrin receptor binding polypeptides
|
AU2018220736A1
(en)
|
2017-02-20 |
2019-09-05 |
Dragonfly Therapeutics, Inc. |
Proteins binding HER2, NKG2D and CD16
|
CA3052837A1
(en)
|
2017-02-28 |
2018-09-07 |
Seattle Genetics, Inc. |
Cysteine mutated antibodies for conjugation
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
AU2018235838B2
(en)
|
2017-03-16 |
2023-12-14 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
CA3064567A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2020529832A
(en)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain
|
EP3694870A1
(en)
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
EA202090974A1
(en)
|
2017-10-18 |
2020-08-05 |
Элпайн Иммьюн Сайенсиз, Инк. |
VARIANT IMMUNOMODULATING PROTEINS OF ICOS LIGAND AND ACCOMPANYING COMPOSITIONS AND METHODS
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
KR20200096253A
(en)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
US11952422B2
(en)
|
2017-12-05 |
2024-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
MX2020006976A
(en)
|
2018-01-12 |
2020-10-05 |
Amgen Inc |
Pac1 antibodies and uses thereof.
|
CN112368012A
(en)
|
2018-02-08 |
2021-02-12 |
蜻蜓疗法股份有限公司 |
Antibody variable domains targeting NKG2D receptor
|
US20220025037A1
(en)
*
|
2018-04-03 |
2022-01-27 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CR20200510A
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc |
Growth differentiation factor 15 fusion proteins
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
TW202015726A
(en)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
WO2020045545A1
(en)
*
|
2018-08-29 |
2020-03-05 |
中外製薬株式会社 |
Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
|
WO2020061376A2
(en)
|
2018-09-19 |
2020-03-26 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
JP2022503959A
(en)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
IL-12 heterodimer FC-fusion protein
|
JP2022510276A
(en)
|
2018-11-30 |
2022-01-26 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
CD86 variant immunomodulatory protein and its use
|
IL297818A
(en)
*
|
2018-12-21 |
2023-01-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
MX2021012607A
(en)
|
2019-04-17 |
2022-03-11 |
Alpine Immune Sciences Inc |
Methods and uses of variant icos ligand (icosl) fusion proteins.
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
US20230058982A1
(en)
*
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
WO2021154046A1
(en)
*
|
2020-01-29 |
2021-08-05 |
고려대학교 산학협력단 |
Ph-sensitive fc variant
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
EP4146684A2
(en)
|
2020-05-08 |
2023-03-15 |
Alpine Immune Sciences, Inc. |
April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
CN116133685A
(en)
*
|
2020-05-20 |
2023-05-16 |
酵活生物制药有限公司 |
Immunoglobulin Fc region variants comprising stability enhancing mutations
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
AU2022269139A1
(en)
|
2021-05-07 |
2023-11-16 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
JP7472405B2
(en)
|
2021-06-25 |
2024-04-22 |
中外製薬株式会社 |
Anti-CTLA-4 antibody
|
WO2022270612A1
(en)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
Use of anti-ctla-4 antibody
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|